|
October 13, 2016
|
Highlights from AMCP |
|
Despite the potential biomarkers offer, barriers remain. Read more. |
|
As the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend. Read more. |
|
Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain. Read more. |
Top content
|
|
|
We welcome your feedback!
Please send your comments to:
Aubrey Westgate
Executive Editor
Managed Healthcare Executive
[email protected] |
DISCLAIMER:
This information has been independently developed and provided by the editors of Managed Healthcare Executive. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|
